COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,552 Articles (22,400 medRxiv, 8,152 bioRxiv)

Most recent first Previous |  Page 317: Articles 3161-3170  | Next

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., Aitchison, J.
10.1101/2023.07.14.549041 — Posted: 2023-07-14
Multivalent Exosome based protein vaccine: a "mix and match" approach to epidemic viruses' challenges.
Cacciottolo, M., Hsieh, L.-E., Li, Y., LeCalire, M. J., Nice, J. B., Twaddle, R., Mora, C. L., Young, M., Angeles, J., Lau, C., Jin, C., Elliott, K., sun, m.
10.1101/2023.07.13.548895 — Posted: 2023-07-14
A simulation framework for modeling the within-patient evolutionary dynamics of SARS-CoV-2
Terbot, J. W., Cooper, B. S., Good, J. M., Jensen, J. D.
10.1101/2023.07.13.548462 — Posted: 2023-07-14
Quantifying the impact of hospital catchment area definitions on hospital admissions forecasts: COVID-19 in England, September 2020 - April 2021
Meakin, S., Funk, S.
10.1101/2023.07.12.23292451 — Posted: 2023-07-13
Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis
Taylor, K., Pearson, M., Das, S., Sardell, J., Chocian, K., Gardner, S.
10.1101/2023.07.13.23292611 — Posted: 2023-07-13
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial
Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Nguyen, H. B., Bong, K. C., Imamura, T., Sonoyama, T., Ichihashi, G., Sanaki, T., Tsuge, Y., Uehara, T., Mukae, H.
10.1101/2023.07.11.23292264 — Posted: 2023-07-13
A Population Level Study on the Determinants of COVID-19 Vaccine Hesitancy at the U.S. County Level
Dong, E., Nixon, K., Gardner, L. M.
10.1101/2023.07.12.23292582 — Posted: 2023-07-13
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults in the United States
Kopel, H., Nguyen, V. H., Boileau, C., Bogdanov, A., Winer, I., Ducruet, T., Zeng, N., Bonafede, M., Esposito, D., Martin, D., Rosen, A., Van de Velde, N., Vermund, S., Gravenstein, S., Mansi, J. A.
10.1101/2023.07.12.23292576 — Posted: 2023-07-13
Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty
Oda, Y., Kumagai, Y., Kanai, M., Iwama, Y., Okura, I., Minamida, T., Yagi, Y., Kurosawa, T., Greener, B., Zhang, Y., Walson, J. L.
10.1101/2023.07.13.23292597 — Posted: 2023-07-13
Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2
Roubidoux, E. K., Brigleb, P. H., Vegesana, K., Souquette, A., Whitt, K., Freiden, P., St. Jude Investigative Team, , Green, A., Thomas, P. G., McGargill, M. A., Wolf, J., Schultz-Cherry, S.
10.1101/2023.07.12.548630 — Posted: 2023-07-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).